You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Every day of lost vision is one too many
We have made a long-term commitment to people with vision loss: to help build a brighter future in which eye diseases that cause blindness are treatable and ultimately preventable.
We have built an industry-leading ophthalmology pipeline with gene therapies, cell therapies and other modalities in development across eye diseases where there are limited or no treatment options, including geographic atrophy (GA), Stargardt disease, retinitis pigmentosa and glaucoma.
At Astellas, we believe in the power of collaboration. We work closely with patient organizations, academia, industry leaders and healthcare providers to ensure that patients have the best possible chance to benefit from next-generation therapies.
1Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. Bourne, Rupert et al. The Lancet Global Health, Volume 9, Issue 2, e130 - e143. Accessed via the IAPB Vision Atlas https://www.iapb.org/learn/vision-atlas. Last accessed September 2024.
2World Health Organisation. Blindness and Vision Impairment. Available at:https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment. Last accessed September 2024
3Astellas. Astellas to acquire Ocata Therapeutics. 2015. Available at https://newsroom.astellas.us/2015-11-09-Astellas-to-Acquire-Ocata-Therapeutics. Last accessed November 2020.
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Located in Westborough, Massachusetts, the Astellas Institute for Regenerative Medicine (AIRM) serves as Astellas’ global hub for regenerative medicine and provides biotechnology, medical, and scientific research and development (R&D) services focused on ophthalmology and other serious diseases.
Founded in 2016 following the acquisition of Ocata Therapeutics, AIRM provides R&D services in the field of biotechnology, including medical and scientific research relating to the development and production of cell types, cell extracts, cellular components, and cell culture media3. AIRM is engaged in developing novel cell-, gene-, and aptamer-based therapies designed to repair, replace, or regenerate the function of cells and tissues damaged by injury or disease.
AIRM also operates as a manufacturing site for cell therapy products, supporting the investigation, development, and clinical advancement of cell-based and gene-based approaches for eye diseases and vision loss.
In addition, AIRM provides medical and scientific research information relating to pharmaceutical preparations for the prevention, diagnosis, and treatment of diseases, disorders, and medical conditions, including ophthalmic diseases. This information is generated through AIRM’s research programs and shared through scientific publications, research collaborations, educational initiatives, and other research communications in support of pharmaceutical R&D.
